Breaking News

Tweet TWEET

Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific

Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories,
                             and Star Scientific

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

LONDON, June 24, 2013

LONDON, June 24, 2013 /PRNewswire/ --

On Friday, June 21, 2013, shares in drug manufacturers ended on a mixed note,
tracking the broader market which also finished mixed after witnessing losses
in two successive trading sessions. The major movers included Pharmacyclics
Inc. (NASDAQ: PCYC), United Therapeutics Corporation (NASDAQ: UTHR), Impax
Laboratories Inc. (NASDAQ: IPXL), and Star Scientific Inc. (NASDAQ: STSI). All
these companies are tracked by AAAResearchReports.com. Free technical research
on PCYC, UTHR, IPXL, and STSI can be downloaded upon sign up at

http://www.aaaresearchreports.com/register/ 

Shares in Pharmacyclics Inc. ended slightly lower on Friday, extending their
losses from previous trading sessions. The company's shares oscillated between
$78.23 and $81.96 before closing the day at $81.00, down 0.36%. A total of
1.05 million shares were traded which is above the daily average volume of
739,954. Pharmacyclics' shares have now declined by over 8.20% in the last
three sessions. Sign up today to read free research report on PCYC at:

http://www.AAAResearchReports.com/PCYC062413.pdf

United Therapeutics Corporation's stock posted modest gains on Friday,
reversing some of its losses from previous market sessions. The company's
shares ended the day at $63.34, up 0.19%, after trading between $62.78 and
$64.55. A total of 818,292 shares were traded which is above the daily average
volume of 567,754. United Therapeutics' shares have slipped by more than 3.50%
in the last three trading sessions. However, despite the recent losses, the
stock is still up 3.92% in the last three months. Register to download free
technical analysis on UTHR at:

http://www.AAAResearchReports.com/UTHR062413.pdf

Shares in Impax Laboratories Inc. moved higher on Friday, paring some of its
losses from its previous two trading sessions. The company's shares traded
between $17.69 and $18.22 before finishing the day 0.72% higher at $18.09. A
total of 1.54 million shares were traded which is above the daily average
volume of 1.15 million. Impax's shares have now fallen more than 4% in the
last three sessions. In the last three months, the stock has gained over
15.80%, thus outperforming the S&P 500. Additionally, shares of the company
are currently trading slightly above their 50-day moving average. A free
report on IPXL can be accessed by registering at:

http://www.AAAResearchReports.com/IPXL062413.pdf

Star Scientific Inc.'s stock rose sharply on Friday, closing 1.53% higher at
$1.33 after trading between $1.24 and $1.33. A total of 1.73 million shares
were traded which is above the daily average volume of 1.07 million. However,
despite the sharp rise on Friday, the company's shares have fallen by 8.28% in
the last three trading sessions. Moreover, the stock is also trading above its
50-day and 200-day moving average. Register with AAA Research Reports and
download the research on STSI for free at:

http://www.AAAResearchReports.com/STSI062413.pdf

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE AAA Research Reports

Contact: AAAresearchreports.com Phone #: +1(646)396-9126
 
Press spacebar to pause and continue. Press esc to stop.